Clinical Relevance of Pathogens Detected by Multiplex PCR in Blood of Very-Low-Birth Weight Infants with Suspected Sepsis – Multicentre Study of the German Neonatal Network

Birte Tröger1*, Christoph Härtel1*, Jan Buer2, Michael Dördelmann3, Ursula Felderhoff-Müser4, Thomas Höhn5, Nico Hepping6, Georg Hillebrand7, Angela Kribs8, Janina Marissen1, Dirk Olbertz9, Peter-Michael Rath2, Susanne Schmidtke10, Jens Siegel11, Egbert Herting1, Wolfgang Göpel1, Joerg Steinmann2, Anja Stein4

1 Department of Pediatrics at the University of Lübeck, Lübeck, Germany, 2 Institute of Medical Microbiology, University of Duisburg-Essen, Essen, Germany, 3 Department of Pediatrics at Diakonissen Hospital Flensburg, Flensburg, Germany, 4 Department of Pediatrics, University Hospital Essen, University Duisburg-Essen, Essen, Germany, 5 Department of Pediatrics at the University of Düsseldorf, Düsseldorf, Germany, 6 Department of Pediatrics at St. Marien Hospital Bonn, Bonn, Germany, 7 Department of Pediatrics at Hospital of Itzehoe, Itzehoe, Germany, 8 Department of Pediatrics at the University of Cologne, Cologne, Germany, 9 Neonatology Unit at St. Marien Hospital Rostock, Rostock, Germany, 10 Neonatology Unit at Aaseiropi Hospital Hamburg-Barmbek, Hamburg, Germany, 11 Neonatology Unit at the Children’s Hospital Hannover Auf der Bult, Hannover, Germany

* These authors contributed equally to this work.

Abstract

Introduction

In the German Neonatal Network (GNN) 10% of very-low-birth weight infants (VLBWI) suffer from blood-culture confirmed sepsis, while 30% of VLBWI develop clinical sepsis. Diagnosis of sepsis is a difficult task leading to potential over-treatment with antibiotics. This study aims to investigate whether the results of blood multiplex-PCR (SeptiFast™) for common sepsis pathogens are relevant for clinical decision making when sepsis is suspected in VLBWI.

Methods

We performed a prospective, multi-centre study within the GNN including 133 VLBWI with 214 episodes of suspected late onset sepsis (LOS). In patients with suspected sepsis a multiplex-PCR (LightCycler SeptiFast MGRADE-test™) was performed from 100 μl EDTA blood in addition to center-specific laboratory biomarkers. The attending neonatologist documented whether the PCR-result, which was available after 24 to 48 hrs, had an impact on the choice of antibiotic drugs and duration of therapy.
Results

PCR was positive in 110/214 episodes (51%) and blood culture (BC) was positive in 55 episodes (26%). Both methods yielded predominantly coagulase-negative staphylococci (CoNS) followed by Escherichia coli and Staphylococcus aureus. In 214 BC—PCR paired samples concordant results were documented in 126 episodes (59%; n = 32 were concordant pathogen positive results, n = 94 were negative in both methods). In 65 episodes (30%) we found positive PCR results but negative BCs, with CoNS being identified in 43 (66%) of these samples. Multiplex-PCR results influenced clinical decision making in 30% of episodes, specifically in 18% for the choice of antimicrobial therapy and in 22% for the duration of antimicrobial therapy.

Conclusions

Multiplex-PCR results had a moderate impact on clinical management in about one third of LOS-episodes. The main advantage of multiplex-PCR was the rapid detection of pathogens from micro-volume blood samples. In VLBWI limitations include risk of contamination, lack of resistance testing and high costs. The high rate of positive PCR results in episodes of negative BC might lead to overtreatment of infants which is associated with risk of mortality, antibiotic resistance, fungal sepsis and NEC.

Introduction

Sepsis continues to be a major cause of mortality and long-term morbidity in very-low-birth-weight infants (VLBW, birth weight < 1500 g). Under well-standardized neonatal intensive care unit conditions the incidence of blood culture (BC) proven sepsis in VLBWI is 10–20% while 30–50% of VLBWI develop clinical sepsis [1, 2]. Early diagnosis of sepsis and prompt empirical therapy with anti-infective drugs are often life-saving. Since highly reliable biomarkers for sepsis in VLBWI are lacking, antibiotic treatment is often initiated because of unspecific clinical signs alone. If the treatment is continued for at least 5 days without BC-confirmed pathogenic growth, diagnosis of “clinical sepsis” is made [3, 4]. BC remains the ‘gold-standard’ for the diagnosis of bloodstream infection. Its sensitivity, however, is limited in VLBWI due to small sample volume, pre-treatment with antibiotics or intermittent bacteremia. In addition to that, results of BCs may take up to 48–72 hours until positive results can be reported [5, 6]. Advances in molecular microbiology have provided culture-independent molecular assays for rapid diagnosis of the causative agent of infection. PCR-assays developed for specific detection of pathogens in the blood were described as early as 1993 [7]. The development of broad-spectrum PCR-assays facilitates more universal detection of microorganisms [8]. In adult patients with suspected sepsis rapid detection of the 25 most common sepsis pathogens (bacterial and fungal) in blood by nucleic acid amplification (e.g. SeptiFast®) has had relevant impact on subsequent management [9, 10]. In neonates detection of bacterial DNA in blood samples is suggested to represent a rapid method in diagnosing sepsis [11, 12]. In line with that, Kasper et al. demonstrated that PCR results are reliable from micro volume samples as small as 100 μl [13]. However, it is largely unknown to what extent availability of PCR results would influence clinical decision making. In the present multicentre study, we evaluated the clinical value of a multiplex-real-time-PCR assay in episodes of suspected late-onset sepsis in VLBWI.
Methods

Study population

The German Neonatal Network (GNN) is a well-established, prospective multicentre collaboration. This prospective study was offered to all study centres during the two year study period (1\textsuperscript{st} of May 2012 until 30\textsuperscript{th} of April 2014). Eleven centres participated and sent samples of VLBWI with clinically suspected sepsis ≥ 72 hours of life after informed written parental consent. Samples were analysed at the Institute of Medical Microbiology, University of Duisburg-Essen. A predefined clinical and laboratory data set of 62 parameters was recorded for each patient on clinical record files (onset of symptoms, clinical and laboratory signs of infection, devices (central or peripheral venous lines, endotracheal tubes, non-invasive ventilation), nutrition, pathogens, site of pathogen detection, diagnosis, antimicrobial therapy, therapy adjustment and other treatments). Data quality was approved by regular on-site monitoring of participating centres by a physician trained in neonatology including cross-check of local microbiological read-outs. In the tables, parameters were included with > 90% full clinical data sets available.

Inclusion criteria

GNN-VLBWI (birth weight < 1500 g and gestational age ≤ 36+6 weeks) with an episode of suspected sepsis ≥ 72 hours of life (LOS, late onset sepsis) were included when blood culture results and multiplex-PCR results were available. Infants with lethal abnormalities and exclusively early onset sepsis (EOS, sepsis within the first 72 hours of life) were not considered for this study.

Definitions and main outcome

For the diagnosis "sepsis" the definitions of the Surveillance Protocol NEO-KISS of Robert-Koch Institute (RKI) were used in preterm infants (www.nrz-hygiene.de) Specifically, BC confirmed sepsis was defined as clinical sepsis with proof of causative agent in BC. If coagulase-negative staphylococci (CoNS) were isolated as single pathogen in one peripheral BC, two clinical signs and one laboratory sign (platelet count < 100/nl, C-reactive protein > 20 mg/L, immature/total neutrophil ratio > 0.2, white blood cell count < 5/nl) were required for classification of CoNS sepsis. Diagnosis of "clinical sepsis" without detection of pathogens in BC was based on 2 clinical parameters, no other focus and the need for at least 5 days of anti-infective treatment \cite{3, 4}. In patients with suspected sepsis a multiplex-PCR (LightCycler SeptiFast MGRADE-test\textsuperscript{R}) was performed from 100 μl EDTA blood in addition to center-specific laboratory biomarkers. The attending neonatologist documented whether the PCR-result, which was available after 24 to 48 hrs during weekdays, had an impact on the choice of antibiotic drugs and duration of therapy (main outcome).

Sample collection and transport

In patients with suspected LOS centre-specific laboratory parameters (such as interleukin 6, C-reactive protein, full blood count) and a BC were taken. In addition, a blood sample for the multiplex-PCR (SeptiFast-test\textsuperscript{R}) was obtained (100–200 μl EDTA blood was collected in DNA-free Sarstedt Microvette\textsuperscript{E} tubes, Nümbrecht, Germany). Blood samples were taken by peripheral venipuncture. To ensure antiseptic blood collection conditions, skin disinfection with octenidine 0.1% with an exposure time of 60 sec was recommended in VLBWI. The BC was sent as usual to the attending microbiological laboratory. Blood samples for multiplex-PCR were immediately stored at 3–7 degrees Celsius and sent with cooling elements to the
Institute of Medical Microbiology, University of Duisburg-Essen, Essen, Germany. Transportation time varied between 6–24 hours.

**Multiplex-PCR**

The SeptiFast®-test (LightCycler® Roche Diagnostics, Mannheim, Germany) uses real-time multiplex PCR to detect more than 20 different pathogens in blood [14]. The diagnostic probes for PCR target the internal transcribed sequences situated between 16S and 23S bacterial ribosomal RNA as well as between 18S and 5.6S fungal ribosomal RNA [15]. The limits for detection of skin bacteria as CoNS and *Streptococcus* spp. were 100 CFU/ml and 30 CFU/ml for all other pathogens. The protocol has been adapted especially for small amounts of blood from 100 μl and contains control samples, which can exclude contamination during preparation. To ensure quality of methodology, tests regarding DNA contamination were performed using normal saline. Multiplex-PCR detected no DNA.

**Ethical approval**

Ethical approval was given by the University of Lübeck Ethical Committee and local ethical committees at the other study centers. Specifically: Ethical Board of the University of Kiel, Ethical Board of the University of Essen, Ethical Board of the University of Düsseldorf, Ethical Board of the University of Bonn, Ethical Board of the Medical Chamber of Hamburg, Ethical Board of the University of Cologne, Ethical Board of the Medical Board of the University of Rostock, Ethical Board of the Medical School Hannover. Informed written consent was given by parents (as legal representatives) on behalf of their infants.

**Statistical analysis**

Data analysis was performed using the SPSS 20.0 data analysis package (Munich, Germany). The chi-square test, Fisher’s exact test and Mann-Whitney U test were applied for statistical analysis of differences between different groups. The level of significance was defined as \( p < 0.05 \) in single comparisons.

**Results**

**Clinical characteristics and signs of infection**

In Table 1, the clinical characteristics of the multicentre study cohort (n = 133 VLBWI, 214 LOS episodes) are described.

Median gestational age of VLBWI was 25.6 weeks and median birth weight was 730 grams. Onset of infection symptoms occurred at a median of 19 days of life. The predominant clinical symptoms for LOS were increased number of desaturations (63.3%) and increased numbers of bradycardias (53.5%), respectively. These clinical signs were accompanied by blood glucose level > 140 mg/dl (25.6%) and elevated C-reactive protein levels (43.7%; Table 2). C-reactive protein levels were documented as maximum levels during LOS episodes and ranged from 3 mg/l to 280 mg/l.

Based on NEOKISS definitions, sepsis episodes were finally classified as clinical sepsis (27.9%), CoNS sepsis (13.0%) and BC proven sepsis with other bacteria (9.8%) (Table 3).

**Isolated pathogens**

Multiplex-PCR was positive in 110 episodes (51%) and BC was positive in 55 episodes (26%) (Table 4).
Table 1. Clinical characteristics of the VLBW cohort with suspected LOS.

|                              | VLBWI with suspected LOS |
|------------------------------|--------------------------|
| Number of infants            | 133                      |
| Number of LOS—episodes       | 214                      |
| Gestational age (median/interquartile range in weeks) | 25.6 / 24.5–28.4 |
| Birth weight (median/interquartile range in grams)     | 730 / 555–1030          |
| Gender (male, %)             | 46.5                     |
| Onset of clinical symptoms (median/interquartile range in days) | 19 / 10–41             |
| Clinical signs of infection (%) |                          |
| Desaturations                | 63.3                     |
| Increased numbers of bradycardias < 80 bpm              | 53.5                     |
| Increased numbers of apneas > 20 sec                     | 38.6                     |
| Grey skin colour              | 33.5                     |
| Abdominal distension         | 33.5                     |
| Apathy/lethargy               | 33.0                     |
| Temperature instability      | 28.4                     |
| Fever                        | 28.4                     |
| Capillary refill time > 2 sec | 27.0                     |
| Tachypnea                    | 27.0                     |
| Tachycardia > 200 bpm        | 20.9                     |
| Reduced feeding tolerance    | 12.1                     |
| Vomiting                      | 10.7                     |

doi:10.1371/journal.pone.0159821.t001

Table 2. Laboratory signs of infection of the VLBW cohort with suspected Late-onset sepsis (LOS).

| Laboratory signs of infection (%) | VLBWI with suspected LOS |
|----------------------------------|--------------------------|
| C-reactive protein > 20 mg/l     | 43.7                     |
| Blood glucose level > 140 mg/dl  | 25.6                     |
| Interleukin-6 elevated           | 18.6                     |
| Thrombocytopenia < 100/nl        | 15.3                     |
| I/T-Ratio > 0.2                  | 14.4                     |
| Base excess < -10 mval/l         | 8.8                      |
| Leukopenia <5/nl                 | 6.5                      |

doi:10.1371/journal.pone.0159821.t002

Table 3. Final diagnosis of the VLBW cohort with suspected LOS episodes.

| Final diagnosis                                | VLBWI with suspected LOS (%) |
|------------------------------------------------|-----------------------------|
| Clinical sepsis                                | 27.9                        |
| Coagulase negative Staphylococci (CoNS)-sepsis | 13.0                        |
| Blood culture positive sepsis                  | 9.8                         |
| Focal intestinal perforation (FIP)             | 4.2                         |
| Necrotizing enterocolitis (NEC)                | 3.7                         |
| Histologically confirmed FIP/NEC              | 5.1                         |
| Pneumonia                                      | 5.6                         |
| Meningitis                                     | 0.9                         |
| Other infectious focus                         | 1.4                         |
| No infection                                   | 33.5                        |

doi:10.1371/journal.pone.0159821.t003
15 samples showed polymicrobial positive multiplex-PCR. In 7 out of 15 multiplex-PCR samples BC detected no pathogen, in 7 out of 15 samples one of the pathogens detected with multiplex-PCR was found in BCs as well. In the remaining sample BC and multiplex-PCR revealed different pathogens. The pathogenic spectrum is outlined in Table 4. Both methods yielded predominantly CoNS followed by *Escherichia coli* and *Staphylococcus aureus*. BCs revealed more often *Corynebacteriae* and *Bifidobacteriae*.

### Concordance of multiplex-PCR and blood culture results

In 214 BC—PCR paired samples concordant results were documented in 126 episodes (n = 32 were concordant pathogen positive results, n = 94 were negative in both methods). In 65 episodes (30.3%) we found positive PCR results but negative BCs, with CoNS being identified in 43 (66.1%) of these samples (Table 5). In those episodes the clinicians made the following final diagnoses: no infection in 23 episodes, clinical sepsis in 22 episodes, CoNS sepsis in 9 episodes and other entities in 11 episodes. Detailed information is given in Table 6. In 13 episodes multiplex-PCR and BC were positive, but the results were not concordant. In 10 samples with positive BC, multiplex-PCR yielded negative results. Pathogens detected were CoNS (n = 9) and *Enterococcus faecalis* (n = 1). Only one case with CoNS-positive BC and negative multiplex-PCR was

### Table 4. Pathogens identified by multiplex-PCR or blood culture.

| Species                                           | Multiplex-PCR (n/%) | Blood culture (n/%) |
|---------------------------------------------------|---------------------|---------------------|
| Coagulase-negative Staphylococci (CoNS)           | 73 / 57.4           | 36 / 65.4           |
| *Escherichia coli*                                 | 11 / 8.6            | 7 / 12.7            |
| *Staphylococcus aureus*                           | 11 / 8.6            | 6 / 10.9            |
| *Enterobacter cloacae*                            | 10 / 7.8            | 1 / 1.8             |
| *Enterococcus faecalis*                           | 7 / 5.5             | 3 / 5.4             |
| *Klebsiella pneumoniae*                           | 7 / 5.5             | 0                   |
| *Streptococcus pneumoniae*                        | 5 / 3.9             | 0                   |
| *Aspergillus fumigatus*                           | 1 / 0.7             | 0                   |
| *Corynebacteriae*                                 | 0                   | 1 / 1.8             |
| *Bifidobacteriae*                                 | 0                   | 1 / 1.8             |
| **Total**                                         | 125#                | 55                  |

*15 multiplex-PCR samples yielded polymicrobial results which are included in the table

*Species which cannot be detected by multiplex PCR

doi:10.1371/journal.pone.0159821.t004

### Table 5. Pathogens identified by multiplex-PCR with negative blood culture result.

| Species                                           | Multiplex-PCR (n) |
|---------------------------------------------------|-------------------|
| Coagulase-negative Staphylococci (CoNS)           | 43                |
| *Staphylococcus aureus*                           | 4                 |
| *Enterobacter cloacae*                            | 6                 |
| *Enterococcus faecalis*                           | 4                 |
| *Klebsiella pneumoniae*                           | 3                 |
| *Streptococcus pneumoniae*                        | 4                 |
| *Aspergillus fumigatus*                           | 1                 |
| **Total**                                         | 65 #              |

*5 multiplex-PCR samples yielded polymicrobial results which are included in the table

doi:10.1371/journal.pone.0159821.t005
classified as ‘no infection’ and CoNS was considered as contaminant. All other BC results represented clinically relevant infections. A fungal pathogen was detected only once with multiplex-PCR and was considered as contamination.

Treatment adjustments

In 208/214 episodes clinicians had documented whether multiplex-PCR had an impact on the choice of antibiotic drugs and/or duration of therapy. As such, multiplex-PCR results influenced clinical decision making in 63 out of 208 episodes with suspected LOS (30%). Choice of antimicrobial therapy was influenced in 37 of 208 (18%) and duration of antimicrobial therapy in 46 of 208 LOS episodes (22%). In episodes with both BC and multiplex-PCR concordant positive result (n = 30 with available information on treatment adjustments), multiplex-PCR influenced clinical decision making in 12 episodes (40%), specifically choice of antimicrobial therapy in 10 episodes (30%) and duration of antimicrobial therapy in 5 out of 30 episodes (17%). The influence of multiplex-PCR result was mainly due to the earlier result compared to BC. Regarding episodes with positive multiplex-PCR and negative BC (n = 62 (n = 62 with available information on treatment adjustments), multiplex-PCR results were important for therapy in 27 out of 62 episodes (42%), for choice of antimicrobial therapy in 18 out of 62 episodes (29%) and in 16 out of 62 (25%) for the duration of therapy.

Discussion

Appropriate and timely antibiotic treatment in LOS is crucial to reduce morbidity and mortality in VLWBI. Here, we present a multi-centre study investigating the clinical relevance of multiplex-PCR (SeptiFast®-test) results in VLWBI with episodes of suspected LOS sepsis. Our data imply that multiplex-PCR is feasible from low-volume samples of VLWBI with suspected LOS in a multi-center setting. Moreover, integration of multiplex-PCR data into clinical routine has a moderate impact on therapeutic judgement. BCs were positive in 26% of all samples in comparison to 51% with multiplex-PCR. The higher rates of pathogen detection using multiplex-PCR in comparison to BCs have been described in various studies [11, 12, 16]. BC positivity data were compatible with previous studies in VLWBI cohorts [2, 17–19]. Concordance between BC and multiplex-PCR (59%) results proved to be lower than in other studies, which reported concordance > 75% [9, 20]. Multiplex-PCR was negative in 10 episodes with positive blood culture. Only one case with CoNS-positive BC and negative multiplex-PCR was classified as ‘no infection’ and CoNS was considered as a contaminant. All other BC results represented clinically significant infections. It is important to note, that all pathogens identified in BCs are

Table 6. Pathogens identified by multiplex-PCR with negative blood culture result and corresponding final diagnosis.

| Species                      | No infection (n) | Clinical sepsis (n) | CoNS sepsis (n) | Other entities (n) |
|------------------------------|------------------|---------------------|-----------------|-------------------|
| Coagulase-negative Staphylococci (CoNS) | 17               | 9                   | 9               | 8 (n = 2 pneumonia; n = 2 abdominal wound infection; n = 3 unspecific viral infection; n = 1 CNS infection) |
| *Staphylococcus aureus*      | 1                | 2                   | 1 (n = 1 pneumonia) |
| *Enterobacter cloacae*       | 3                | 3                   |                 |                   |
| *Enterococcus faecalis*      | 2                | 2                   | 2 (n = 2 unspecific viral infection) |
| *Klebsiella pneumoniae*      |                  |                     |                 |                   |
| *Streptococcus* spp.         | 1                | 3                   |                 |                   |
| *Aspergillus fumigatus*      | 1                |                     |                 |                   |
| Total (n)                    | 23               | 22                  | 9               | 11                |

doi:10.1371/journal.pone.0159821.t006
part of the multiplex-PCR spectrum. This may possibly have occurred due to genetic variability among the pathogens, or mutations of the target site, inappropriate sample preparation or prolonged transport times. We evaluated if transportation time could have had an influence on multiplex-PCR detection rate. Four samples with positive BC and negative multiplex-PCR were sent from the Department of Pediatrics, University Hospital of Essen and multiplex-PCR was performed at the Institute of Medical Microbiology, University of Essen which is located at the same campus. Transportation time of these samples was the shortest, making an influence of transportation time unlikely. Other samples with positive BC and negative multiplex-PCR were sent from Düsseldorf (n = 3), Cologne (n = 1) and Lübeck (n = 2). Transportation time was between 6–24 hours and did not differ with respect to the other centers. The “sensitivity” aspect may also be related to PCR detection limits of skin bacteria. CoNS and Streptococcus spp. were detected only at 100 CFU/ml and the sensitivity limit was 30 CFU/ml for all other pathogens (set up by the manufacturer to avoid detection of contaminants). In 30.3% of LOS-episodes we found positive multiplex-PCR results and corresponding negative BCs. It has been described that the use of molecular assays has the risk of detecting contaminant DNA, thereby producing false-positive results [8]. Despite several advantages of PCR-based methods, a potential limitation of these molecular assays is the detection of DNA from dead/non-viable microorganisms, resulting in false-positive results and potentially leading to overuse of antibiotics which is associated with the risk for antibiotic resistance, fungal sepsis, NEC and mortality [21, 22, 23]. This is a clinically relevant issue, although a recent report on multiplex-PCR detection of pathogen DNA in blood has convincingly related DNA presence to the actual infection status of the patient [24]. Hence interpretation of multiplex-PCR results should always be assessed in a context with other laboratory data and clinical conditions of the patient. In our study CoNS was the main pathogen identified in 66% of PCR-positive/BC-negative samples. In 35% of cases with positive multiplex-PCR and negative BCs clinicians finally decided that no infection was present. In 34% diagnosis of clinical sepsis and in 14% diagnosis of CoNS-sepsis was made. Different study groups observed higher rate of positive results by multiplex-PCR compared to BC in patients undergoing antimicrobial therapy [11]. Tschiedel et al. [25] showed in 2012 that detection rate via blood culture in paediatric patients under antibiotic therapy was only half as high as in patients without antimicrobial treatment. It is a known problem, that cultivation of bacteria and fungi under anti-infective therapy is rarely successful [16]. In our study, there was no exact evaluation regarding prior therapies and residuals of antimicrobials in blood samples. Importantly, multiplex-PCR data were available 24-48h after blood withdrawal during week-days. The results led to adjustment of initial therapy in 30% of VLBWI with suspected LOS. Therapy modifications were more often performed when CoNS were detected by multiplex-PCR. However, whether therapeutic adjustments initiated by the multiplex-PCR had an impact on clinical outcomes was not determined in this study. Our study has some limitations. It was a non-randomized assessment, and therefore a selection bias cannot be excluded which may have influenced the rate and spectrum of pathogens found in our cohort. We did not have an exact evaluation regarding antimicrobial pre-treatment, although VLBWI are often managed with empirical antibiotic therapy and results of BCs may be influenced by antimicrobial therapy. Evaluation of multiplex-PCR in pre-treated VLBWI with suspected LOS including assessment of antimicrobial remnants (in blood or urine) would be an important future project. Patient’s characteristics in our study are comparable to those of other sepsis studies in VLBWI [2] and pathogens identified were characteristic for the group of VLBWI and their risk factors. Another limitation results from the fact that sample volumes for BC were not standardized (0.1-1ml). It is known that the sensitivity of BC results correlates with the acquired blood volumes and the number of inoculated bottles. Costs for multiplex-PCR testing are approximately 5 times as high as for a pair of BCs and specially trained staff is
necessary to perform multiplex-PCR. The most important advantage of BC over multiplex-PCR is, that susceptibility testing of an isolate can be performed, allowing the implementation of specifically targeted antimicrobial or antifungal therapy. BC also has an advantage over multiplex-PCR with respect to microorganisms not included. However, bacteria or fungi which were not included in the SeptiFast pattern have only been detected twice.

Conclusion

Addition of multiplex-PCR to conventional BCs had a moderate impact on clinical management in about one third of LOS-episodes. The main advantage of multiplex-PCR was the rapid detection of pathogens from micro-volume blood samples. In preterm infants limitations include limited spectrum of pathogens, risk of contamination, lack of resistance testing and high costs. Specifically, the high rate of positive PCR results in episodes of negative blood culture might lead to overtreatment of infants which is associated with risk of mortality, antibiotic resistance, fungal sepsis and NEC.

Author Contributions

Conceived and designed the experiments: BT CH JS (seventeenth author) AS WG. Performed the experiments: JB PMR JS (seventeenth author). Analyzed the data: BT CH WG JM. Contributed reagents/materials/analysis tools: BT CH MD UF-M NH GH TH AK DO SS JS (fourteenth author). Wrote the paper: BT CH AS JS (seventeenth author) EH.

References

1. Boghossian NS, Page GP, Bell EF, Stoll BJ, Murray JC, Cotten CM et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births. J Pediatr. 2013; 1120–4, 1124.e1. doi: 10.1016/j.jpeds.2012.11.089 PMID: 23324523

2. Tröger B, Göpel W, Faust K, Müller T, Jorch G, Felderhoff-Müser U et al. Risk for late-onset blood-culture proven sepsis in very-low-birth weight infants born small for gestational age: a large multicenter study from the German Neonatal Network. Pediatr Infect Dis J. 2014; doi: 10.1097/INF.0000000000000031

3. Schwab F, Geffers C, Barwolff S, Ruden H, Gastmeier P. Reducing neonatal nosocomial bloodstream infections through participation in a national surveillance system. J Hosp Infect 2007; 65: 319–325. PMID: 17350730.

4. Geffers C, Baerwolff S, Schwab F, Gastmeier P. Incidence of healthcare-associated infections in high risk neonates: results from the German surveillance system for very-low-birthweight infants. J Hosp Infect 2008; 68: 214–221. doi: 10.1016/j.jhin.2008.01.016 PMID: 19289725.

5. Peters R. P., van Agtmael M. A., Danner S. A., Savelkoul P. H., and Vandenbroucke-Grauls C. M.. New developments in the diagnosis of bloodstream infections. Lancet Infect. Dis. 2004; 4: 751–760. PMID: 15567125

6. Mussap M. New diagnostic tools for neonatal sepsis: the role of a real-time polymerase chain reaction for the early detection and identification of bacterial and fungal species in blood samples. J Chemother. 2007; 19:31–34. PMID: 18073177

7. Song JH, Cho H, Park MY, Na DS, Moon HB, Pai CH. Detection of Salmonella typhi in the blood of patients with typhoid fever by polymerase chain reaction. J Clin Microbiol. 1993; 31(6):1439–43. PMID: 8314983

8. Klaschik S, Lehmann LE, Raadts A, Book M, Gebel J, Hoeft A, Stuber F. Detection and differentiation of in vitro-spiked bacteria by real-time PCR and melting-curve analysis. J Clin Microbiol. 2004; 42 (2):512–7. PMID: 14766809

9. Dierkes C, Ehrenstein B, Siebig S, Linde HJ, Reischl U, Salzberger B. Clinical impact of a commercially available multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis. BMC Infect Dis 2009; 11:126–132.

10. Idelevich EA, Silling G, Niederbracht Y, Penner H, Sauerland MC, Tafelski S et al. Molecular Diagnostics of Sepsis study group. Impact of multiplex PCR on antimicrobial treatment in febrile neutropenia: a
11. Lucignano B, Ranno S, Liesenfeld O, Pizzorno B, Putignani L, Bernaschi P, Menichella D. Multiplex PCR allows rapid and accurate diagnosis of bloodstream infections in newborns and children with suspected sepsis. J Clin Microbiol. 2011; 2252–8. doi: 10.1128/JCM.02460-10 PMID: 21471340

12. Reier-Nilsen T, Farstad T, Nakstad B, Lauvrak V, Steinbakk M. Comparison of broad range 16S rDNA PCR and conventional blood culture for diagnosis of sepsis in the newborn: a case control study. BMC Pediatr. 2009; 9:5. doi: 10.1186/1471-2431-9-5 PMID: 19152691

13. Kasper DC, Altok I, Mechtler TP, Böhmm J, Straub J, Langgartner M, Pollak A, Herkner KR, Berger A. Molecular detection of late-onset neonatal sepsis in premature infants using small blood volumes: proof-of-concept. Neonatology. 2013; 103(4):268–73. doi: 10.1159/000346365 PMID: 23485823

14. Lehmann LE, Hunfeld KP, Emrich T, Haberenhausen G, Wissing H, Hoeft A et al. Multiplex real-time PCR assay for rapid detection and differentiation of 25 bacterial and fungal pathogens from whole blood samples. Med Microbiol Immunol. 2008; 197(3):313–324. doi: 10.1007/s00430-007-0063-0 PMID: 18008085

15. Chang SS, Hsieh WH, Liu TS, Lee SH, Wang CH, Chou HC et al. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis—a systemic review and meta-analysis. PLoS One. 2013; 8(5):e62323. doi: 10.1371/journal.pone.0062323 PMID: 23734173

16. Westh H, Lisby G, Breyssse F, Böddinghaus B, Chomarat M, Gant V et al. Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin Microbiol Infect. 2009; 544–51. doi: 10.1111/j.1469-0691.2009.02736.x PMID: 19392905

17. Faust K, Göpel W, Herting E, Härtel C. Sepsis bei Frühgeborenen mit einem sehr niedrigen Geburtsgewicht. Chemotherapy J 2011; 20: 1–8.

18. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110: 285–91. PMID: 12165580

19. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002–2003. Pediatr Infect Dis J 2005; 24: 635–639. PMID: 15999007

20. Mancini N, Clerici D, Diotti R, Perotti M, Ghidoli N, De Marco D et al. Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies. J Med Microbiol. 2008; 57(Pt 5):601–4. doi: 10.1099/jmm.0.47732-0 PMID: 18436593

21. Cantey JB, Patel SJ. Antimicrobial stewardship in the NICU. Infect Dis Clin North Am 2014; 28:247–261. doi: 10.1016/j.idc.2014.01.005 PMID: 24857391

22. Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely-low-birth-weight infants. Pediatrics 2006; 118:717–722. PMID: 16882828

23. Härtel C, Hartz A, Bah L, Gille C, Gortner L, Simon A et al. German Neonatal Network. Media Stories on NICU Outbreaks Lead to an Increased Prescription Rate of Third-Line Antibiotics in the Community of Neonatal Care. Infect Control Hosp Epidemiol. 2016; 4:1–7.

24. Tsakal E. L.. Multiplex PCR to diagnose bloodstream infections in patients admitted from the emergency department with sepsis. J. Clin. Microbiol. 2010; 48:26–33. doi: 10.1128/JCM.01447-09 PMID: 19846634

25. Tschiedel E, Steinmann J, Buer J, Onnebrink JG, Felderhoff-Müser U, Rath PM et al. Results and relevance of molecular detection of pathogens by SeptiFast—a retrospective analysis in 75 critically ill children. Klin Padiatr. 2012; 224(1):12–6. doi: 10.1055/s-0031-1285878. PMID: 22258624